THE PBAC has recommended streamlined authority listings for cancer therapies BMS' Opdivo (nivolumab) and Roche's MabThera (rituximab) - see pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Apr 17